Cover Image
市場調查報告書

20S蛋白解體:開發中產品分析

20s Proteasome - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 363576
出版日期 內容資訊 英文 69 Pages
訂單完成後即時交付
價格
Back to Top
20S蛋白解體:開發中產品分析 20s Proteasome - Pipeline Review, H2 2016
出版日期: 2016年10月19日 內容資訊: 英文 69 Pages
簡介

本報告提供20S蛋白解體藥物的開發情形相關資訊,提供您各開發階段,藥物標的,作用機制,給藥途徑及分子類型別分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

20S蛋白解體概要

治療藥的開發

20S蛋白解體:開發中的產品 - 各開發階段

20S蛋白解體:開發中的產品 - 治療範圍別

20S蛋白解體:開發中的產品 - 各適應症

20S蛋白解體:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

20S蛋白解體:企業開發中的產品

20S蛋白解體:治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

20S蛋白解體治療藥的開發企業

  • Amgen Inc.
  • LG Life Science LTD.

20S蛋白解體:藥物簡介

20S蛋白解體:暫停中的計劃

20S蛋白解體:主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0595TDB

Summary

Global Markets Direct's, '20s Proteasome - Pipeline Review, H2 2016', provides in depth analysis on 20s Proteasome targeted pipeline therapeutics.

The report provides comprehensive information on the 20s Proteasome , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in 20s Proteasome targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for 20s Proteasome
  • The report reviews 20s Proteasome targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in 20s Proteasome targeted therapeutics and enlists all their major and minor projects
  • The report assesses 20s Proteasome targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to 20s Proteasome targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for 20s Proteasome
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding 20s Proteasome development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • 20s Proteasome Overview
  • Therapeutics Development
    • 20s Proteasome - Products under Development by Stage of Development
    • 20s Proteasome - Products under Development by Therapy Area
    • 20s Proteasome - Products under Development by Indication
  • 20s Proteasome - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • 20s Proteasome - Products under Development by Companies
  • 20s Proteasome - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • 20s Proteasome - Companies Involved in Therapeutics Development
    • Amgen Inc.
    • LG Life Science LTD.
    • Triphase Accelerator Corporation
  • 20s Proteasome - Drug Profiles
    • carfilzomib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • marizomib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • oprozomib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit 20S Proteasome for Multiple Myeloma and Solid Tumor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VPE-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VPEA-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VPEA-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VR-23 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • 20s Proteasome - Dormant Projects
  • 20s Proteasome - Featured News & Press Releases
    • Sep 27, 2016: Amgen Announces Top-Line Results From Phase 3 KYPROLIS (Carfilzomib) CLARION Study In Newly Diagnosed Multiple Myeloma Patients
    • Sep 07, 2016: ONO Launches KYPROLIS for Intravenous Injection 10 mg and 40 mg Proteasome Inhibitor
    • Sep 07, 2016: ONO Submits Supplemental New Drug Application in Japan for "KYPROLIS for Intravenous Injection 10 mg and 40 mg", a Proteasome Inhibitor, for Relapsed or Refractory Multiple Myeloma
    • Jul 04, 2016: ONO Receives Manufacturing and Marketing Approval in Japan for KYPROLIS, a Proteasome Inhibitor, in Relapsed or Refractory Multiple Myeloma
    • Jul 03, 2016: European Commission Approves Extended Indication For Amgen's Kyprolis (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Patients
    • Jun 10, 2016: New Analyses From Pivotal Phase 3 Studies Show Kyprolis (Carfilzomib) Allows Patients With Relapsed Multiple Myeloma To Live Longer Without Disease Progression
    • Jun 09, 2016: Preliminary data for pre-kidney transplant being presented June 13
    • Jun 06, 2016: New Phase 3 Secondary Analysis Shows Progression-Free Survival Benefit In Early Relapsing Multiple Myeloma Patients Treated With Kyprolis (Carfilzomib)-Based Regimen
    • Jun 04, 2016: Triphase Accelerator Corporation Announces Positive Results of Phase 1 Trial of Marizomib and Bevacizumab in Malignant Glioma
    • Jun 03, 2016: Amgen Announces Launch Of KYPROLIS (carfilzomib) CENTRAL, An Online News Resource Demonstrating The Impact Of Relapsed Multiple Myeloma On The Lives Of Patients And Caregivers
    • May 27, 2016: Amgen Receives Positive CHMP Opinion To Extend Indication Of Kyprolis (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma
    • May 26, 2016: Kyprolis (Carfilzomib) Demonstrates Economic Value In Relapsed Or Refractory Multiple Myeloma Manuscript Published In "Journal of Medical Economics"
    • May 19, 2016: Amgen Highlights Data on Kyprolis at 21st Congress Of The European Hematology Association
    • May 18, 2016: Amgen To Present Data on Kyprolis (carfilzomib) At ASCO 2016
    • Apr 19, 2016: Triphase Accelerator Corporation Announces Positive Interim Results of Phase 1 Trial of Marizomib and Bevacizumab in Malignant Glioma
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Amgen Inc., H2 2016
  • Pipeline by LG Life Science LTD., H2 2016
  • Pipeline by Triphase Accelerator Corporation, H2 2016
  • Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top